Table 4.
Baseline Characteristics of 526 High‐risk Patients According to Baseline Pulse Amplitude
| Mean Baseline | P Value | ||
|---|---|---|---|
| High Mean Baseline 857< (n=263) | Low Mean Baseline ≤857 (n=263) | ||
| Age, mean (SD), y | 67.6 (10.3) | 66.7 (11.0) | 0.324 |
| Male sex, no. (%) | 187 (71.1) | 177 (67.3) | 0.395 |
| Body mass index, mean (SD), kg/m2 | 24.4 (3.2) | 24.0 (3.7) | 0.199 |
| Hypertension, no. (%) | 214 (81.4) | 213 (81.0) | >0.99 |
| Diabetes, no. (%) | 127 (48.3) | 119 (45.2) | 0.541 |
| Dyslipidemia, no. (%) | 218 (82.9) | 219 (83.3) | >0.99 |
| Current smoking, no. (%) | 55 (20.9) | 57 (21.7) | 0.915 |
| Family history of CAD, no. (%) | 69 (26.2) | 61 (23.2) | 0.479 |
| Systolic BP, mean (SD), mm Hg | 130.6 (18.2) | 127.7 (18.4) | 0.076 |
| Diastolic BP, mean (SD), mm Hg | 72.8 (11.5) | 72.5 (12.5) | 0.783 |
| Hemoglobin A1c, mean (SD), % | 6.4 (1.0) | 6.4 (1.0) | 0.788 |
| Total/HDL cholesterol ratio, mean (SD) | 3.7 (1.1) | 3.7 (1.1) | 0.974 |
| LDL cholesterol, mean (SD), mg/dL | 104.4 (30.8) | 106.0 (32.4) | 0.576 |
| HDL cholesterol, mean (SD), mg/dL | 51.7 (14.7) | 52.0 (14.6) | 0.814 |
| Triglycerides, median (IQR), mg/dL | 118 (86 to 154) | 113 (80 to 156) | 0.713 |
| LVEF, mean (SD), % | 63.8 (6.6) | 63.5 (7.2) | 0.646 |
| BNP, median (IQR), pg/mL | 28.3 (14.8 to 57.6) | 27.9 (11.7 to 63.4) | 0.482 |
| hsCRP, median (IQR), mg/L | 0.70 (0.30 to 1.80) | 0.78 (0.33 to 1.76) | 0.711 |
| eGFR, mean (SD), mL/min per 1.73 m2 | 66.8 (17.6) | 67.8 (18.8) | 0.565 |
| Aspirin, no. (%) | 222 (84.4) | 211 (80.2) | 0.253 |
| HMG‐CoA RIs, no. (%) | 189 (71.9) | 183 (69.6) | 0.632 |
| CCB, no. (%) | 145 (55.1) | 160 (60.8) | 0.216 |
| ACE‐I or ARB, no. (%) | 147 (55.9) | 148 (56.3) | >0.99 |
| β‐blockers, no. (%) | 121 (46.0) | 106 (40.3) | 0.218 |
| Anti‐diabetic drugs, no. (%) | 91 (34.6) | 82 (31.2) | 0.458 |
| Coronary artery disease, no. (%) | 227 (86.3) | 213 (81.0) | 0.125 |
| FRS, median (IQR), % | 9.0 (5.0 to 11.0) | 8.0 (3.0 to 11.0) | 0.059 |
| SYNTAXsc, median (IQR) | 14.0 (5.0 to 20.0) | 12.0 (5.0 to 19.0) | 0.156 |
| SYNTAXsc ≥23, no. (%) | 51 (19.4) | 40 (15.2) | 0.249 |
| Baseline Pulse Amplitude, mean (SD) | 1226 (304) | 573 (187) | <0.0001 |
| Cardiovascular events, no. (%) | 50 (19.0) | 54 (20.5) | 0.663 |
Data are the mean (SD), median values (25th to 75th percentile range), or no. (%). Significance was assessed by an unpaired t test, the Mann‐Whitney U test or Fisher's exact test. ACE‐I indicates angiotensin‐converting enzyme‐inhibitors; ARB, angiotensin II receptor blockers; BNP, B‐type natriuretic peptide; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blockers; eGFR, estimated glomerular filtration rate; FRS, Framingham Risk Score; HDL, high‐density lipoprotein; HMG‐CoA RIs, hydroxymethylglutaryl‐CoA reductase inhibitors; hsCRP, high‐sensitivity C‐reactive protein; IQR, interquartile range; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; SD, standard deviation; SYNTAXsc, Synergy Between PCI With Taxus and Cardiac Surgery score.